Xinyue (Sherry) Liu

Dr. Xinyue (Sherry) Liu


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 August 2022 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
PWPeng Wang
Peng Wang
EKEsra Karakose
Esra Karakose
CACarmen Argmann
Carmen Argmann
HWHuan Wang
Huan Wang
MBMetodi Balev
Metodi Balev
ASAndrew F. Stewart
Andrew F. Stewart
Resistance to regeneration of insulin-producing pancreatic β cells is a fundamental challenge for type 1 and type 2 diabetes. Recently, small molecule inhibitors of the kinase DYRK1A have proven effective in inducing adult human β cells to proliferate, but their detailed mechanism of action is incompletely understood. We interrogated our human insulinoma and β cell transcriptomic databases seeking to understand why β cells in insulinomas proliferate, while normal β cells do not. This search reveals the DREAM complex as a central regulator of quiescence in human β cells. The DREAM complex consists of a module of transcriptionally repressive proteins that assemble in response to DYRK1A kinase activity, thereby inducing and maintaining cellular quiescence. In the absence of DYRK1A, DREAM subunits reassemble into the pro-proliferative MMB complex. Here, we demonstrate that small molecule DYRK1A inhibitors induce human β cells to replicate by converting the repressive DREAM complex to its pro-proliferative MMB conformation.

1 June 2019 in Transplantation
Verified
Journal Article
Open access
TSTimothy M. Sladden
Timothy M. Sladden
Stephanie YerkovichStephanie Yerkovich
Stephanie Yerkovich
MGMichelle Grant
Michelle Grant
Fuming ZhangFuming Zhang
Fuming Zhang
XLXinyue (Sherry) Liu
Xinyue (Sherry) Liu
DCDaniel C Chambers
Daniel C Chambers
Background.: The endothelial glycocalyx, a sieve-like structure located on the luminal surface of all blood vessels, has been found to be integral to regulation of capillary permeability and mechanotransduction. Given this, we investigated the role of endothelial glycocalyx breakdown products in organ donors and recipients in terms of acceptability for transplant and risk of primary graft dysfunction (PGD). Methods.: Endothelial glycocalyx breakdown products were measured in the peripheral blood of 135 intended and actual organ donors. Breakdown product levels were tested for association with donor demographic and clinical data, organ acceptability for transplant along with lung recipient outcomes (n = 35). Liquid chromatography mass spectrometry analysis was performed to confirm glycosaminoglycan levels and sulfation patterns on donor samples (n = 15). In transplant recipients (n = 50), levels were measured pretransplant and daily for 4 days posttransplant. Levels were correlated with PGD severity and intubation time. Results.: Decreased hyaluronan levels in peripheral blood independently predicted organ acceptability in intended and actual donors (odds ratio, 0.96; [95% confidence interval, 0.93–0.99] P = 0.026). Furthermore, high donor syndecan-1 levels were associated with PGD in recipients (3142 [1575–4829] versus 6229 [4009–8093] pg/mL; P = 0.045). In recipient blood, levels of syndecan-1 were correlated with severe (grades 2–3) PGD at 72 hours posttransplant (5982 [3016–17191] versus 3060 [2005–4824] pg/mL; P = 0.01). Conclusions.: Endothelial glycocalyx breakdown occurs in lung transplant donors and recipients and predicts organ acceptability and development of PGD. Glycocalyx breakdown products may be useful biomarkers in transplantation, and interventions to protect the glycocalyx could improve transplant outcomes.

28 May 2022 in European Journal of Medical Research
Verified
Journal Article
Open access
PDF file
KLKexin Lyu
Kexin Lyu
TLTianzhu Liu
Tianzhu Liu
YCYixuan Chen
Yixuan Chen
JLJingwei Lu
Jingwei Lu
LJLi Jiang
Li Jiang
Sen LiSen Li
Sen Li
Tendon injuries are widespread and chronic disorders of the musculoskeletal system, frequently caused by overload of the tendons. Currently, the most common treatment for tendon injuries is "cell-free therapy", of which exosomes, which can treat a host of diseases, including immune disorders, musculoskeletal injuries and cardiovascular diseases, are one kind. Among the many sources of exosomes, adipose-derived stem cell exosomes (ASC-Exos) have better efficacy. This is attributed not only to the ease of isolation of adipose tissue, but also to the high differentiation capacity of ASCs, their greater paracrine function, and immunomodulatory capacity compared to other exosomes. ASC-Exos promote tendon repair by four mechanisms: promoting angiogenesis under hypoxic conditions, reducing the inflammatory response, promoting tendon cell migration and proliferation, and accelerating collagen synthesis, thus accelerating tendon healing. This review focuses on describing studies of preclinical experiments with various exosomes, the characteristics of ASC-Exos and their mechanisms of action in tendon healing, as well as elaborating the limitations of ASC-Exos in clinical applications.

9 May 2024 in Journal of Cleaner Production
Verified
Journal Article
Closed access
YLYong-Tao Li
Yong-Tao Li
YWYu-Qin Wang
Yu-Qin Wang
XLXi Li
Xi Li
XLXinyue (Sherry) Liu
Xinyue (Sherry) Liu
HLHao Liu
Hao Liu
WDWanying Du
Wanying Du

1 January 2017 in Journal of Chromatography A
Verified
Journal Article
Closed access
XLXinyue (Sherry) Liu
Xinyue (Sherry) Liu
KAKalib St. Ange
Kalib St. Ange
LLLei Lin
Lei Lin
Fuming ZhangFuming Zhang
Fuming Zhang
LCLianli Chi
Lianli Chi
RLRobert Linhardt
Robert Linhardt